趙鳳蘭 崔凱 鄭濤



[摘要] 目的 探討阿托伐他汀強(qiáng)化治療急性缺血性腦卒中合并糖尿病的臨床效果。方法 選取2018年1月—2019年1月急性缺血性腦卒中合并糖尿病患者70例,將其依據(jù)實(shí)際數(shù)字表法分成對(duì)照組(35例,對(duì)癥治療)與觀察組(35例,阿托伐他汀強(qiáng)化治療),對(duì)比兩組血脂、血糖水平、神經(jīng)功能缺損程度及治療效果。結(jié)果 觀察組治療總有效率較對(duì)照組顯著升高(P<0.05)。觀察組美國(guó)國(guó)立衛(wèi)生研究院卒中量表(NIHSS)評(píng)分明顯低于對(duì)照組(P<0.05)。觀察組低密度脂蛋白膽固醇(LDL-C)、三酰甘油(TG)、總膽固醇(TC)明顯低于對(duì)照組(P<0.05),而高密度脂蛋白膽固醇(HDL-C)水平高于對(duì)照組(P<0.05)。結(jié)論 針對(duì)急性缺血性腦卒中合并糖尿病患者,采用阿托伐他汀強(qiáng)化治療,效果理想。
[關(guān)鍵詞] 缺血性腦卒中;糖尿病;阿托伐他汀
[中圖分類號(hào)] R587.1? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] A? ? ? ? ? [文章編號(hào)] 1672-4062(2020)10(a)-0091-03
[Abstract] Objective To explore the clinical effect of atorvastatin in the intensive treatment of acute ischemic stroke with diabetes. Methods From January 2018 to January 2019, 70 patients with acute ischemic stroke and diabetes were selected and divided into control group (35 cases, symptomatic treatment) and observation group (35 cases, atovar based on the actual number table method Intensive statin treatment), compare the two groups of blood lipids, blood sugar levels, the degree of neurological deficits and treatment effects. Results The total effective rate of treatment in the observation group was significantly higher than that in the control group(P<0.05). The score of the National Institutes of Health Stroke Scale (NIHSS) in the observation group was significantly lower than that in the control group(P<0.05). The low-density lipoprotein cholesterol (LDL-C), triacylglycerol (TG) and total cholesterol (TC) of the observation group were significantly lower than those of the control group(P<0.05), while the high-density lipoprotein cholesterol (HDL-C) level was higher than control group(P<0.05). Conclusion For patients with acute ischemic stroke and diabetes, intensive treatment with atorvastatin is effective.
[Key words] Ischemic stroke; Diabetes; Atorvastatin
急性缺血性腦卒中是一種比較常見(jiàn)且嚴(yán)重的腦部疾病,有著比較高的發(fā)病率、病死率。有報(bào)道[1]指出,糖尿病是誘發(fā)此病的獨(dú)立危險(xiǎn)因素,且認(rèn)為大多糖尿病患者存在不同程度的脂質(zhì)代謝紊亂情況。另?yè)?jù)流行病學(xué)研究證實(shí),急性缺血性卒中的發(fā)生與總膽固醇水平之間,存在著十分緊密的關(guān)系,并且LDL-C的升高與此病關(guān)系更加緊密。當(dāng)前,臨床多采用他汀類藥物治療此病,此類藥除了能實(shí)現(xiàn)低密度脂蛋白、膽固醇的降低之外,還能逆轉(zhuǎn)動(dòng)脈中膜厚度,使動(dòng)脈粥樣硬化斑塊處于穩(wěn)定狀態(tài),因而能有效降低卒中風(fēng)險(xiǎn),穩(wěn)定血脂水平,獲得更好的治療效果。該文針對(duì)2018年1月—2019年1月收治的急性缺血性腦卒中合并糖尿病共計(jì)35例給予阿托伐他汀進(jìn)行強(qiáng)化治療,觀察其應(yīng)用效果,現(xiàn)報(bào)道如下。
1? 資料與方法
1.1? 一般資料
選取來(lái)該院接受治療的急性缺血性腦卒中合并糖尿病患者,共計(jì)70例,納入標(biāo)準(zhǔn):①均與中華醫(yī)學(xué)會(huì)所制定的《中國(guó)急性缺血性腦卒中診治指南》及《中國(guó)2型糖尿病防治指南》中相關(guān)診斷標(biāo)準(zhǔn)相符[2];②經(jīng)頭顱CT、MRI檢查確診;③各項(xiàng)生命體征穩(wěn)定,沒(méi)有抽搐、昏迷癥狀。……